| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Venous Thromboembolism develops before the start of treatment in about 25% of patients with ovarian cancer. Tissue factor (TF), initiates extrinsic blood coagulation. We investigated the intensity of TF expression (ITFE) and VTE in 128 patients with epithelial ovarian cancer. Before starting treatment, all patients were ultrasonographically screened for VTE. The ITFE was graded based on immunostaining of surgical specimens. The prevalence of VTE was significantly higher in CCC (34%) than in non-CCC (17%, P= 0.03). As ITFE increased, the frequencies of CCC and VTE increased significantly (P<0.001 and P=0.014, respectively). Multivariate analysis identified TF expression and pretreatment D-dimer level as significant independent risk factors for VTE development. Expression of TF is high in CCC significantly, and involved in the development of VTE.
|
